(RTTNews) - Senti Biosciences, Inc. (SNTI) on Tuesday announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to SENTI-202, its off-the-shelf CAR-NK therapy being developed for relapsed or refractory AML and other hematologic cancers.
This recognition comes from new Phase 1 data that shows the treatment can specifically target leukemic cells without harming healthy stem cells. It follows Senti's earlier Orphan Drug Designation this year.
The company presented updated SENTI-202 data at the 2025 ASH Annual Meeting, and there's an investor webcast lined up for December 9.
SNTI is currently trading at $2.6083, up $0.2183 or 9.13 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
